Company Infinity Pharmaceuticals, Inc.

Equities

INFI.Q

US45665G3039

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-04-21 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-99.96%

Mar. 25	North American Morning Briefing : Tech in Focus on -2-	DJ
Mar. 25	Infinity Pharmaceuticals, Inc. Went Out of Business	CI

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.

Number of employees: 30

USD in Million	2021	Weight	2022	Weight	Delta
Drug Development 100.0 %	2	100.0 %	3	100.0 %	+39.56%

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	2	100.0 %	3	100.0 %	+39.56%

Managers	Title	Age	Since
Seth Tasker CEO	Chief Executive Officer	45	08-02-29
Jennifer Roberts PRN	Corporate Officer/Principal	-	17-09-30
Melissa Hackel PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Anthony Evnin BRD	Director/Board Member	83	06-08-31
Norman Selby BRD	Director/Board Member	71	12-03-11
David W. Beier BRD	Director/Board Member	75	18-03-31
Richard Gaynor BRD	Director/Board Member	74	20-03-15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	90,761,081	88,284,669 ( 97.27 %)	0	97.27 %

Name	Equities	%	Valuation
Adelene Perkins 1.313 %	1,191,738	1.313 %	119 $
Lawrence Bloch 1.065 %	966,932	1.065 %	97 $
Anthony Evnin 0.2373 %	215,403	0.2373 %	22 $
BG Fund Management Luxembourg SA 0.1108 %	100,606	0.1108 %	10 $
Manulife Investment Management Ltd. 0.0583 %	52,923	0.0583 %	5 $
OrbiMed Advisors LLC 0.0364 %	33,000	0.0364 %	3 $
Brian Schwartz 0.0341 %	30,919	0.0341 %	3 $
Pension Reserves Investment Management Board 0.0232 %	21,044	0.0232 %	2 $
Norman Selby 0.0165 %	15,000	0.0165 %	2 $
Samuel Agresta 0.0117 %	10,593	0.0117 %	1 $

Infinity Pharmaceuticals, Inc.

1100 Massachusetts Avenue 4th Floor

02138, Cambridge

+617 453 1000

http://www.infi.com

address Infinity Pharmaceuticals, Inc.(INFI.Q)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
INFINITY PHARMACEUTICALS, INC.	-99.96%	90
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+44.76%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research